A Phase 1 interventional study of PF-06939926 in Duchenne Muscular Dystrophy, sponsored by Pfizer. Terminated at 22 sites in United States. Open to male participants aged 4 Years and older. Per ClinicalTrials.gov, last updated 2025-09-15.
Sponsored by Pfizer · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 233 studies in Muscular Dystrophy, Duchenne with a site in United States — 35 open to participants now, 61 under way, 8 of them phase 3. Muscular Dystrophy, Duchenne · United States.
Among the 233 studies in Muscular Dystrophy, Duchenne with a site in United States, this one is the 91st largest by enrollment of the 172 interventional ones that give a count, is one of 21 that started in 2018, is one of 32 in phase 1, and was the 118th registered.
482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.
Browse Muscular Dystrophy, Duchenne studies →35 of the 233 studies in Muscular Dystrophy, Duchenne with a site in United States are open now. Recruiting first, the newest first:
Vanderbilt University Medical Center · Sites in United States
Ages 18+ · Men only
Sarepta Therapeutics, Inc. · Sites in United States
Ages 4+ · Men only
University of Florida · Sites in United States
Ages 6+ · Men only
Vanderbilt University Medical Center · Sites in United States
Ages 8–18 · Men only
University of Rochester · Sites in United States
Ages 0 days–3 yrs · Men only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 65 Muscular Dystrophy, Duchenne studies recruiting now, 30 (46%) set no upper age limit and 33 (51%) stop at 75 or younger; 58 take children under 18; 11 take healthy volunteers.
This study: 4 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
233 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 57 · Phase 2 91 · Phase 3 40 · Phase 4 5
First in 2000; this study’s year is marked. 21 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 23 is close to the median of 25 across 333 interventional studies indexed under Muscular Dystrophy, Duchenne.
Median enrollment 25 across the 172 interventional studies, 75 across the 55 observational. Of the 160 that completed or were terminated, 78 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
131 of 233 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 9 studies filed under Muscular Dystrophy, Duchenne — fewer than ten, so there is no comparison to draw.
20 of the studies in Muscular Dystrophy, Duchenne with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05881408Phase 3Sarepta Therapeutics, Inc.A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD) | 2027-05-31 |
| NCT06290713University of FloridaVasodilator and Exercise Study for DMD (VASO-REx) | 2026-11 |
| NCT06450639Hoffmann-La RocheA Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD) | 2026-11-18 |
| NCT03368742Solid Biosciences Inc.Microdystrophin Gene Transfer Study in Adolescents and Children With DMD | 2026-11-30 |
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
Add all 20 to your calendar (.ics) → With an account.
Among the 233 studies in Muscular Dystrophy, Duchenne with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a first-in-human/first-in-patient, multi-center, open-label, non-randomized, ascending dose, safety and tolerability study of a single intravenous infusion of PF-06939926 in ambulatory and non-ambulatory subjects with Duchenne muscular dystrophy (DMD). Other objectives include measurement of dystrophin expression and distribution, and assessments of muscle strength, quality, and function.
A total of approximately 22 subjects will receive PF-06939926, and these will include both ambulatory and non-ambulatory subjects. Up to 13 subjects may be included in a cohort that includes the concomitant medication, sirolimus. In order to mitigate unanticipated risks to subject safety, enrollment will be staggered within and between two planned dose-levels and will include a formal review by an external data monitoring committee (E-DMC) prior to dose progression.
Inclusion Criteria:
Age as follows, based on ambulatory status:
Body weights as follows, based on ambulatory status:
Functional performance as follows, based on ambulatory status:
Exclusion Criteria:
Compromised cardiac function as indicated by on cardiac MRI, as follows, based on ambulatory status:
The following genetic abnormalities in the dystrophin gene as confirmed by the investigator based on the review of the DMD genetic testing:
Sirolimus Cohort
Inclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Genetic: PF-06939926
Recombinant adeno-associated virus, serotype 9 (AAV9) carrying a truncated human dystrophin gene (mini-dystrophin) under the control of a muscle-specific promoter. Subjects will receive a single intravenous infusion of one of 2 dose levels.
Number of Participants With All-Causality Treatment-Emergent Adverse Events (TEAEs) for 1-Year Follow-Up
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Any AE that started following start of treatment of PF-06939926 was counted as a treatment-emergent AE (TEAE). A serious AE (SAE) was an untoward medical occurrence that resulted in death, was life-threatening (immediate risk of death), required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in congenital anomaly/birth defect, or was considered to be an important medical event. Severe AE=an event that prevents normal everyday activities.
Time frame: Baseline up to 1 year post dose of PF-06939926
Number of Participants With All-Causality TEAEs by System Organ Class (SOC) and Preferred Term (PT) for 1-Year Follow-Up
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Any AE that started following start of treatment of PF-06939926 was counted as a TEAE. For this outcome measure, TEAEs were reported according to Medical Dictionary for Regulatory Activities (MedDRA) version 25.0 SOC and PT.
Time frame: Baseline up to 1 year post dose of PF-06939926
Number of Participants With Treatment-Related TEAEs for 1-Year Follow-Up
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Any AE that started following start of treatment of PF-06939926 was counted as a TEAE. An SAE was an untoward medical occurrence that resulted in death, was life-threatening (immediate risk of death), required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in congenital anomaly/birth defect, or was considered to be an important medical event. Severe AE=an event that prevents normal everyday activities. Treatment-related AE was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. Treatment-related AEs and SAEs were determined by the investigator.
Time frame: Baseline up to 1 year post dose of PF-06939926
Number of Participants With Treatment-Related TEAEs by SOC and PT for 1-Year Follow-Up
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Any AE that started following start of treatment of PF-06939926 was counted as a TEAE. For this outcome measure, TEAEs were reported according to MedDRA version 25.0 SOC and PT. Treatment-related AE was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. Treatment-related AEs were determined by the investigator.
Time frame: Baseline up to 1 year post dose of PF-06939926
Number of Participants With All-Causality SAEs by SOC and PT for 1-Year Follow-Up
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Any AE that started following start of treatment of PF-06939926 was counted as a TEAE. An SAE was an untoward medical occurrence that resulted in death, was life-threatening (immediate risk of death), required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in congenital anomaly/birth defect, or was considered to be an important medical event. For this outcome measure, TEAEs were reported according to MedDRA version 25.0 SOC and PT.
Time frame: Baseline up to 1 year post dose of PF-06939926
Number of Participants With Treatment-Related SAEs by SOC and PT for 1-Year Follow-Up
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Any AE that started following start of treatment of PF-06939926 was counted as a TEAE. An SAE was an untoward medical occurrence that resulted in death, was life-threatening (immediate risk of death), required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in congenital anomaly/birth defect, or was considered to be an important medical event. Treatment-related AE was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. Treatment-related AEs and SAEs were determined by the investigator. For this outcome measure, TEAEs were reported according to MedDRA version 25.0 SOC and PT.
Time frame: Baseline up to 1 year post dose of PF-06939926
Number of Participants With Laboratory Test Abnormalities Without Regard to Baseline Abnormality for 1-Year Follow-Up - Hematology
Following hematologic parameters were analyzed for laboratory examination: hemoglobin, hematocrit, red blood cell (RBC) count, platelet count, white blood cell count, total neutrophils, absolute neutrophils (ANC), eosinophils, monocytes, basophils, lymphocytes, red blood cell indices, and haptoglobin. Laboratory abnormalities with occurrence in at least 1 participant are reported for this outcome measure. Baseline was defined as the last pre-dose measurement.
Time frame: Baseline up to 1 year post dose of PF-06939926
Number of Participants With Laboratory Test Abnormalities Without Regard to Baseline Abnormality for 1-Year Follow-Up - Clinical Chemistry
Following parameters for clinical chemistry were analyzed for laboratory examination: blood urea nitrogen (BUN) and creatinine, glucose, calcium, sodium, potassium, chloride, total CO2 (bicarbonate), aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin (direct and indirect bilirubin), alkaline phosphatase, uric acid, albumin, total protein, serum phosphorus, cystatin C, creatine kinase, creatine kinase myocardial b fraction (CK-MB), amylase, lipase, gamma-glutamyl transferase (GGT), C-reactive protein (CRP), and cardiac troponin I. Laboratory abnormalities with occurrence in at least 1 participant are reported for this outcome measure. Baseline was defined as the last pre-dose measurement.
Time frame: Baseline up to 1 year post dose of PF-06939926
Number of Participants With Laboratory Test Abnormalities Without Regard to Baseline Abnormality for 1-Year Follow-Up - Urinalysis
Following parameters for urinalysis were analyzed for laboratory examination: pH, glucose, protein, blood, ketones, nitrites, leukocyte esterase, and microscopy. Laboratory abnormalities with occurrence in at least 1 participant are reported for this outcome measure. Baseline was defined as the last pre-dose measurement.
Time frame: Baseline up to 1 year post dose of PF-06939926
Change From Baseline on Left Ventricular Ejection Fraction as Measured by Cardiac Magnetic Resonance Imaging (MRI) for 1-Year Follow-Up
Cardiac MRI was performed after thigh and upper limb MRI or on separate days within the required visit window. Change in LVEF is presented as percentages, and was calculated as \[(stroke volume) / (end-diastolic volume)\]\*100%. Baseline is defined as the last pre-dose measurement. Change from baseline on Day 360 (ie, 1 year post dose) was reported for this outcome measure.
Time frame: Baseline, 1 year post dose of PF-06839926 (Day 360)
Number of Participants With Electrocardiograms (ECGs) Meeting the Pre-Defined Categorical Criteria for 1-Year Follow-Up
Triplicate ECG was performed after the participant had rested quietly for at least 10 minutes in a supine position. The pre-defined categorical criteria include PR interval aggregate (msec): value\>=300, baseline\>200 and percent change\>=25%, baseline\<=200 and percent change\>=50%; QRS duration aggregate (msec): value\>=140, percent change\>=50%; QTcF interval aggregate (msec): 450\<=value\<480, 480\<=value\<500, value\>=500, 30\<=change\<60, change\>=60. Only the category(ies) with at least 1 participant meeting the pre-defined criterion is/are reported for this outcome measure. Baseline for ECG was defined as the measurement before the Day 1 study drug administration.
Time frame: Baseline up to 1 year post dose of PF-06939926
Number of Participants With Positive Responses on Columbia-Suicide Severity Rating Scale (C-SSRS) According to the Columbia Classification Algorithm of Suicide Assessment (C-CASA) Categories
C-SSRS is a participant rated questionnaire to assess whether participant experienced the following: completed suicide(1), suicide attempt(2)("Yes" on "actual attempt"), preparatory acts toward imminent suicidal behavior(3)("Yes" on "preparatory acts or behavior"), suicidal ideation(4)("Yes" on "wish to be dead","non-specific active suicidal thoughts","active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent), any suicidal behavior or ideation, self-injurious behavior(7)("Yes" on "Has subject engaged in non-suicidal self-injurious behavior"). Yes/No responses are mapped to C-CASA categories. C-SSRS was conducted with the participant's care giver/legal guardian on the participant's behalf throughout the study for participants\<=12 years of age at screening. Baseline is defined as the last predose measurement. Number of participants with responses of "Yes" is reported for this outcome measure.
Time frame: Baseline, Day 7, Day 14, Day 180, and Day 360
Number of Participants With Vital Signs Meeting the Pre-Defined Categorical Criteria for 1-Year Follow-Up
Vital signs consisted of blood pressure, respiratory rate, and heart rate, was obtained with these measurements at the following timepoints: within 30 minutes before and approximately 30 minutes, 1, 2, 4, 8, and 24 hours after the start of the infusion, and on Days 4, 7, 10, 14, 30, 90, 180, and 360. Baseline was defined as the last pre-dose recording. Number of participants who had at least 1 vital sign measurement at the specified timepoints meeting the pre-defined criteria from baseline up to the end of 1-year follow-up is reported for this outcome measure.
Time frame: Baseline up to 1 year post dose of PF-06939926
The study reached its primary completion date (PCD) on 28 Mar 2022. The data cutoff for PCD was on 30 Sep 2022. As of 30 Sep 2022, a total of 22 participants, including 19 ambulatory participants and 3 non-ambulatory participants, were enrolled and assigned to treatment.
| Milestone | PF-06939926: Low Dose, Ambulatory Cohort | PF-06939926: High Dose, Ambulatory Cohort | PF-06939926: High Dose, Non-Ambulatory Cohort |
|---|---|---|---|
| Started | 3 | 16 | 3 |
| Completed | 3 | 16 | 2 |
| Not completed | 0 | 0 | 1 |
| Withdrew: Death | 0 | 0 | 1 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Any AE that started following start of treatment of PF-06939926 was counted as a treatment-emergent AE (TEAE). A serious AE (SAE) was an untoward medical occurrence that resulted in death, was life-threatening (immediate risk of death), required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in congenital anomaly/birth defect, or was considered to be an important medical event. Severe AE=an event that prevents normal everyday activities.
| Participants | PF-06939926: Low Dose, Ambulatory Cohort | PF-06939926: High Dose, Ambulatory Cohort | PF-06939926: High Dose, Non-Ambulatory Cohort |
|---|---|---|---|
| TEAEs | 3 | 16 | 3 |
| SAEs | 0 | 3 | 2 |
| Severe AEs | 1 | 2 | 2 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Any AE that started following start of treatment of PF-06939926 was counted as a TEAE. For this outcome measure, TEAEs were reported according to Medical Dictionary for Regulatory Activities (MedDRA) version 25.0 SOC and PT.
| Participants | PF-06939926: Low Dose, Ambulatory Cohort | PF-06939926: High Dose, Ambulatory Cohort | PF-06939926: High Dose, Non-Ambulatory Cohort |
|---|---|---|---|
| SOC: BLOOD AND LYMPHATIC SYSTEM DISORDERS, Total | 2 | 9 | 1 |
| SOC: BLOOD AND LYMPHATIC SYSTEM DISORDERS, PT: Anaemia | 0 | 2 | 0 |
| SOC: BLOOD AND LYMPHATIC SYSTEM DISORDERS, PT: Haemolysis | 0 | 1 | 0 |
| SOC: BLOOD AND LYMPHATIC SYSTEM DISORDERS, PT: Haemolytic uraemic syndrome | 0 | 0 | 1 |
| SOC: BLOOD AND LYMPHATIC SYSTEM DISORDERS, PT: Leukocytosis | 1 | 0 | 0 |
| SOC: BLOOD AND LYMPHATIC SYSTEM DISORDERS, PT: Lymphopenia | 1 | 0 | 0 |
| SOC: BLOOD AND LYMPHATIC SYSTEM DISORDERS, PT: Thrombocytopenia | 0 | 9 | 0 |
| SOC: CARDIAC DISORDERS, Total | 0 | 0 | 2 |
| SOC: CARDIAC DISORDERS, PT: Cardiogenic shock | 0 | 0 | 1 |
| SOC: CARDIAC DISORDERS, PT: Cardiomyopathy | 0 | 0 | 1 |
| SOC: ENDOCRINE DISORDERS, Total | 0 | 1 | 0 |
| SOC: ENDOCRINE DISORDERS, PT: Androgen deficiency | 0 | 1 | 0 |
| SOC: EYE DISORDERS, Total | 0 | 0 | 1 |
| SOC: EYE DISORDERS, PT: Lacrimation increased | 0 | 0 | 1 |
| SOC: GASTROINTESTINAL DISORDERS, Total | 3 | 15 | 3 |
| SOC: GASTROINTESTINAL DISORDERS, PT: Abdominal pain | 0 | 1 | 0 |
| SOC: GASTROINTESTINAL DISORDERS, PT: Abdominal pain lower | 0 | 1 | 0 |
| SOC: GASTROINTESTINAL DISORDERS, PT: Abdominal pain upper | 0 | 3 | 2 |
| SOC: GASTROINTESTINAL DISORDERS, PT: Constipation | 0 | 3 | 0 |
| SOC: GASTROINTESTINAL DISORDERS, PT: Diarrhoea | 0 | 3 | 0 |
| SOC: GASTROINTESTINAL DISORDERS, PT: Gastrooesophageal reflux disease | 0 | 1 | 0 |
| SOC: GASTROINTESTINAL DISORDERS, PT: Inguinal hernia | 1 | 0 | 0 |
| SOC: GASTROINTESTINAL DISORDERS, PT: Nausea | 2 | 8 | 3 |
| SOC: GASTROINTESTINAL DISORDERS, PT: Toothache | 1 | 0 | 0 |
| SOC: GASTROINTESTINAL DISORDERS, PT: Vomiting | 2 | 13 | 3 |
| SOC: GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS, Total | 2 | 11 | 1 |
| SOC: GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS, PT: Chest pain | 0 | 0 | 1 |
| SOC: GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS, PT: Fatigue | 1 | 6 | 0 |
| SOC: GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS, PT: Infusion site reaction | 0 | 1 | 0 |
| SOC: GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS, PT: Mass | 0 | 1 | 0 |
| SOC: GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS, PT: Pyrexia | 1 | 8 | 0 |
| SOC: HEPATOBILIARY DISORDERS, Total | 0 | 2 | 1 |
| SOC: HEPATOBILIARY DISORDERS, PT: Liver injury | 0 | 2 | 1 |
| SOC: INFECTIONS AND INFESTATIONS, Total | 0 | 7 | 1 |
| SOC: INFECTIONS AND INFESTATIONS, PT: Cellulitis | 0 | 1 | 0 |
| SOC: INFECTIONS AND INFESTATIONS, PT: Conjunctivitis | 0 | 1 | 0 |
| SOC: INFECTIONS AND INFESTATIONS, PT: Influenza | 0 | 1 | 0 |
| SOC: INFECTIONS AND INFESTATIONS, PT: Molluscum contagiosum | 0 | 1 | 0 |
| SOC: INFECTIONS AND INFESTATIONS, PT: Nasopharyngitis | 0 | 2 | 0 |
| SOC: INFECTIONS AND INFESTATIONS, PT: Parainfluenzae virus infection | 0 | 0 | 1 |
| SOC: INFECTIONS AND INFESTATIONS, PT: Sinusitis | 0 | 3 | 0 |
| SOC: INFECTIONS AND INFESTATIONS, PT: Tooth abscess | 0 | 1 | 0 |
| SOC: INFECTIONS AND INFESTATIONS, PT: Urinary tract infection | 0 | 0 | 1 |
| SOC: INFECTIONS AND INFESTATIONS, PT: Viral upper respiratory tract infection | 0 | 1 | 0 |
| SOC: INJURY, POISONING AND PROCEDURAL COMPLICATIONS, Total | 0 | 6 | 1 |
| SOC: INJURY, POISONING AND PROCEDURAL COMPLICATIONS, PT: Contusion | 0 | 1 | 0 |
| SOC: INJURY, POISONING AND PROCEDURAL COMPLICATIONS, PT: Fall | 0 | 5 | 0 |
| SOC: INJURY, POISONING AND PROCEDURAL COMPLICATIONS, PT: Joint dislocation | 0 | 1 | 0 |
| SOC: INJURY, POISONING AND PROCEDURAL COMPLICATIONS, PT: Joint injury | 0 | 1 | 0 |
| SOC: INJURY, POISONING AND PROCEDURAL COMPLICATIONS, PT: Ligament sprain | 0 | 1 | 0 |
| SOC: INJURY, POISONING AND PROCEDURAL COMPLICATIONS, PT: Post procedural contusion | 0 | 1 | 0 |
| SOC: INJURY, POISONING AND PROCEDURAL COMPLICATIONS, PT: Procedural pain | 0 | 0 | 1 |
| SOC: INJURY, POISONING AND PROCEDURAL COMPLICATIONS, PT: Skin abrasion | 0 | 1 | 0 |
| SOC: INVESTIGATIONS, Total | 0 | 6 | 2 |
| SOC: INVESTIGATIONS, PT: Amylase increased | 0 | 1 | 0 |
| SOC: INVESTIGATIONS, PT: Complement factor C4 decreased | 0 | 5 | 0 |
| SOC: INVESTIGATIONS, PT: Cystatin C increased | 0 | 1 | 0 |
| SOC: INVESTIGATIONS, PT: Glutamate dehydrogenase increased | 0 | 3 | 0 |
| SOC: INVESTIGATIONS, PT: Hepatic enzyme increased | 0 | 0 | 1 |
| SOC: INVESTIGATIONS, PT: Lipase increased | 0 | 1 | 0 |
| SOC: INVESTIGATIONS, PT: Troponin increased | 0 | 0 | 1 |
| SOC: METABOLISM AND NUTRITION DISORDERS, Total | 2 | 8 | 0 |
| SOC: METABOLISM AND NUTRITION DISORDERS, PT: Decreased appetite | 2 | 6 | 0 |
| SOC: METABOLISM AND NUTRITION DISORDERS, PT: Dehydration | 0 | 5 | 0 |
| SOC: METABOLISM AND NUTRITION DISORDERS, PT: Hyperuricaemia | 0 | 1 | 0 |
| SOC: MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS, Total | 2 | 3 | 2 |
| SOC: MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS, PT: Arthralgia | 0 | 0 | 2 |
| SOC: MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS, PT: Back pain | 0 | 0 | 1 |
| SOC: MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS, PT: Myalgia | 0 | 1 | 0 |
| SOC: MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS, PT: Osteopenia | 1 | 0 | 0 |
| SOC: MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS, PT: Pain in extremity | 1 | 1 | 0 |
| SOC: NERVOUS SYSTEM DISORDERS, Total | 2 | 7 | 3 |
| SOC: NERVOUS SYSTEM DISORDERS, PT: Dizziness | 1 | 0 | 0 |
| SOC: NERVOUS SYSTEM DISORDERS, PT: Headache | 0 | 7 | 3 |
| SOC: NERVOUS SYSTEM DISORDERS, PT: Lethargy | 1 | 0 | 0 |
| SOC: NERVOUS SYSTEM DISORDERS, PT: Migraine | 0 | 1 | 0 |
| SOC: PSYCHIATRIC DISORDERS, Total | 2 | 3 | 0 |
| SOC: PSYCHIATRIC DISORDERS, PT: Abnormal behaviour | 0 | 1 | 0 |
| SOC: PSYCHIATRIC DISORDERS, PT: Affect lability | 1 | 1 | 0 |
| SOC: PSYCHIATRIC DISORDERS, PT: Anxiety | 0 | 1 | 0 |
| SOC: PSYCHIATRIC DISORDERS, PT: Irritability | 0 | 1 | 0 |
| SOC: PSYCHIATRIC DISORDERS, PT: Mood altered | 1 | 0 | 0 |
| SOC: PSYCHIATRIC DISORDERS, PT: Suicidal ideation | 0 | 1 | 0 |
| SOC: RENAL AND URINARY DISORDERS, Total | 0 | 4 | 0 |
| SOC: RENAL AND URINARY DISORDERS, PT: Acute kidney injury | 0 | 1 | 0 |
| SOC: RENAL AND URINARY DISORDERS, PT: Chronic kidney disease | 0 | 1 | 0 |
| SOC: RENAL AND URINARY DISORDERS, PT: Glycosuria | 0 | 1 | 0 |
| SOC: RENAL AND URINARY DISORDERS, PT: Haematuria | 0 | 2 | 0 |
| SOC: RENAL AND URINARY DISORDERS, PT: Ketonuria | 0 | 2 | 0 |
| SOC: RENAL AND URINARY DISORDERS, PT: Proteinuria | 0 | 2 | 0 |
| SOC: RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS, Total | 0 | 4 | 0 |
| SOC: RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS, PT: Cough | 0 | 2 | 0 |
| SOC: RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS, PT: Epistaxis | 0 | 1 | 0 |
| SOC: RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS, PT: Oropharyngeal pain | 0 | 1 | 0 |
| SOC: RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS, PT: Rhinorrhoea | 0 | 1 | 0 |
| SOC: SKIN AND SUBCUTANEOUS TISSUE DISORDERS, Total | 0 | 3 | 1 |
| SOC: SKIN AND SUBCUTANEOUS TISSUE DISORDERS, PT: Ecchymosis | 0 | 0 | 1 |
| SOC: SKIN AND SUBCUTANEOUS TISSUE DISORDERS, PT: Rash | 0 | 2 | 0 |
| SOC: SKIN AND SUBCUTANEOUS TISSUE DISORDERS, PT: Urticaria | 0 | 1 | 0 |
| SOC: VASCULAR DISORDERS, Total | 0 | 2 | 0 |
| SOC: VASCULAR DISORDERS, PT: Hypertension | 0 | 2 | 0 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Any AE that started following start of treatment of PF-06939926 was counted as a TEAE. An SAE was an untoward medical occurrence that resulted in death, was life-threatening (immediate risk of death), required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in congenital anomaly/birth defect, or was considered to be an important medical event. Severe AE=an event that prevents normal everyday activities. Treatment-related AE was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. Treatment-related AEs and SAEs were determined by the investigator.
| Participants | PF-06939926: Low Dose, Ambulatory Cohort | PF-06939926: High Dose, Ambulatory Cohort | PF-06939926: High Dose, Non-Ambulatory Cohort |
|---|---|---|---|
| TEAEs | 3 | 15 | 3 |
| SAEs | 0 | 3 | 2 |
| Severe AEs | 0 | 2 | 2 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Any AE that started following start of treatment of PF-06939926 was counted as a TEAE. For this outcome measure, TEAEs were reported according to MedDRA version 25.0 SOC and PT. Treatment-related AE was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. Treatment-related AEs were determined by the investigator.
| Participants | PF-06939926: Low Dose, Ambulatory Cohort | PF-06939926: High Dose, Ambulatory Cohort | PF-06939926: High Dose, Non-Ambulatory Cohort |
|---|---|---|---|
| SOC: BLOOD AND LYMPHATIC SYSTEM DISORDERS, Total | 2 | 9 | 1 |
| SOC: BLOOD AND LYMPHATIC SYSTEM DISORDERS, PT: Anaemia | 0 | 2 | 0 |
| SOC: BLOOD AND LYMPHATIC SYSTEM DISORDERS, PT: Haemolysis | 0 | 1 | 0 |
| SOC: BLOOD AND LYMPHATIC SYSTEM DISORDERS, PT: Haemolytic uraemic syndrome | 0 | 0 | 1 |
| SOC: BLOOD AND LYMPHATIC SYSTEM DISORDERS, PT: Leukocytosis | 1 | 0 | 0 |
| SOC: BLOOD AND LYMPHATIC SYSTEM DISORDERS, PT: Lymphopenia | 1 | 0 | 0 |
| SOC: BLOOD AND LYMPHATIC SYSTEM DISORDERS, PT: Thrombocytopenia | 0 | 9 | 0 |
| SOC: CARDIAC DISORDERS, Total | 0 | 0 | 1 |
| SOC: CARDIAC DISORDERS, PT: Cardiogenic shock | 0 | 0 | 1 |
| SOC: GASTROINTESTINAL DISORDERS, Total | 2 | 15 | 3 |
| SOC: GASTROINTESTINAL DISORDERS, PT: Abdominal pain | 0 | 1 | 0 |
| SOC: GASTROINTESTINAL DISORDERS, PT: Abdominal pain upper | 0 | 3 | 1 |
| SOC: GASTROINTESTINAL DISORDERS, PT: Diarrhoea | 0 | 1 | 0 |
| SOC: GASTROINTESTINAL DISORDERS, PT: Nausea | 2 | 8 | 3 |
| SOC: GASTROINTESTINAL DISORDERS, PT: Vomiting | 2 | 13 | 3 |
| SOC: GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS, Total | 2 | 11 | 0 |
| SOC: GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS, PT: Fatigue | 1 | 6 | 0 |
| SOC: GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS, PT: Infusion site reaction | 0 | 1 | 0 |
| SOC: GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS, PT: Pyrexia | 1 | 8 | 0 |
| SOC: HEPATOBILIARY DISORDERS, Total | 0 | 2 | 1 |
| SOC: HEPATOBILIARY DISORDERS, PT: Liver injury | 0 | 2 | 1 |
| SOC: INVESTIGATIONS, Total | 0 | 6 | 2 |
| SOC: INVESTIGATIONS, PT: Amylase increased | 0 | 1 | 0 |
| SOC: INVESTIGATIONS, PT: Complement factor C4 decreased | 0 | 5 | 0 |
| SOC: INVESTIGATIONS, PT: Cystatin C increased | 0 | 1 | 0 |
| SOC: INVESTIGATIONS, PT: Glutamate dehydrogenase increased | 0 | 3 | 0 |
| SOC: INVESTIGATIONS, PT: Hepatic enzyme increased | 0 | 0 | 1 |
| SOC: INVESTIGATIONS, PT: Lipase increased | 0 | 1 | 0 |
| SOC: INVESTIGATIONS, PT: Troponin increased | 0 | 0 | 1 |
| SOC: METABOLISM AND NUTRITION DISORDERS, Total | 2 | 8 | 0 |
| SOC: METABOLISM AND NUTRITION DISORDERS, PT: Decreased appetite | 2 | 6 | 0 |
| SOC: METABOLISM AND NUTRITION DISORDERS, PT: Dehydration | 0 | 5 | 0 |
| SOC: METABOLISM AND NUTRITION DISORDERS, PT: Hyperuricaemia | 0 | 1 | 0 |
| SOC: NERVOUS SYSTEM DISORDERS, Total | 2 | 1 | 3 |
| SOC: NERVOUS SYSTEM DISORDERS, PT: Dizziness | 1 | 0 | 0 |
| SOC: NERVOUS SYSTEM DISORDERS, PT: Headache | 0 | 1 | 3 |
| SOC: NERVOUS SYSTEM DISORDERS, PT: Lethargy | 1 | 0 | 0 |
| SOC: RENAL AND URINARY DISORDERS, Total | 0 | 4 | 0 |
| SOC: RENAL AND URINARY DISORDERS, PT: Acute kidney injury | 0 | 1 | 0 |
| SOC: RENAL AND URINARY DISORDERS, PT: Chronic kidney disease | 0 | 1 | 0 |
| SOC: RENAL AND URINARY DISORDERS, PT: Glycosuria | 0 | 1 | 0 |
| SOC: RENAL AND URINARY DISORDERS, PT: Haematuria | 0 | 2 | 0 |
| SOC: RENAL AND URINARY DISORDERS, PT: Ketonuria | 0 | 2 | 0 |
| SOC: RENAL AND URINARY DISORDERS, PT: Proteinuria | 0 | 2 | 0 |
| SOC: VASCULAR DISORDERS, Total | 0 | 2 | 0 |
| SOC: VASCULAR DISORDERS, PT: Hypertension | 0 | 2 | 0 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Any AE that started following start of treatment of PF-06939926 was counted as a TEAE. An SAE was an untoward medical occurrence that resulted in death, was life-threatening (immediate risk of death), required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in congenital anomaly/birth defect, or was considered to be an important medical event. For this outcome measure, TEAEs were reported according to MedDRA version 25.0 SOC and PT.
| Participants | PF-06939926: Low Dose, Ambulatory Cohort | PF-06939926: High Dose, Ambulatory Cohort | PF-06939926: High Dose, Non-Ambulatory Cohort |
|---|---|---|---|
| SOC: BLOOD AND LYMPHATIC SYSTEM DISORDERS, Total | 0 | 1 | 1 |
| SOC: BLOOD AND LYMPHATIC SYSTEM DISORDERS, PT: Haemolytic uraemic syndrome | 0 | 0 | 1 |
| SOC: BLOOD AND LYMPHATIC SYSTEM DISORDERS, PT: Thrombocytopenia | 0 | 1 | 0 |
| SOC: CARDIAC DISORDERS, Total | 0 | 0 | 1 |
| SOC: CARDIAC DISORDERS, PT: Cardiogenic shock | 0 | 0 | 1 |
| SOC: INFECTIONS AND INFESTATIONS, Total | 0 | 0 | 1 |
| SOC: INFECTIONS AND INFESTATIONS, PT: Urinary tract infection | 0 | 0 | 1 |
| SOC: METABOLISM AND NUTRITION DISORDERS, Total | 0 | 1 | 0 |
| SOC: METABOLISM AND NUTRITION DISORDERS, PT: Dehydration | 0 | 1 | 0 |
| SOC: RENAL AND URINARY DISORDERS, Total | 0 | 1 | 0 |
| SOC: RENAL AND URINARY DISORDERS, PT: Acute kidney injury | 0 | 1 | 0 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Any AE that started following start of treatment of PF-06939926 was counted as a TEAE. An SAE was an untoward medical occurrence that resulted in death, was life-threatening (immediate risk of death), required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in congenital anomaly/birth defect, or was considered to be an important medical event. Treatment-related AE was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. Treatment-related AEs and SAEs were determined by the investigator. For this outcome measure, TEAEs were reported according to MedDRA version 25.0 SOC and PT.
| Participants | PF-06939926: Low Dose, Ambulatory Cohort | PF-06939926: High Dose, Ambulatory Cohort | PF-06939926: High Dose, Non-Ambulatory Cohort |
|---|---|---|---|
| SOC: BLOOD AND LYMPHATIC SYSTEM DISORDERS, Total | 0 | 1 | 1 |
| SOC: BLOOD AND LYMPHATIC SYSTEM DISORDERS, PT: Haemolytic uraemic syndrome | 0 | 0 | 1 |
| SOC: BLOOD AND LYMPHATIC SYSTEM DISORDERS, PT: Thrombocytopenia | 0 | 1 | 0 |
| SOC: CARDIAC DISORDERS, Total | 0 | 0 | 1 |
| SOC: CARDIAC DISORDERS, PT: Cardiogenic shock | 0 | 0 | 1 |
| SOC: METABOLISM AND NUTRITION DISORDERS, Total | 0 | 1 | 0 |
| SOC: METABOLISM AND NUTRITION DISORDERS, PT: Dehydration | 0 | 1 | 0 |
| SOC: RENAL AND URINARY DISORDERS, Total | 0 | 1 | 0 |
| SOC: RENAL AND URINARY DISORDERS, PT: Acute kidney injury | 0 | 1 | 0 |
Following hematologic parameters were analyzed for laboratory examination: hemoglobin, hematocrit, red blood cell (RBC) count, platelet count, white blood cell count, total neutrophils, absolute neutrophils (ANC), eosinophils, monocytes, basophils, lymphocytes, red blood cell indices, and haptoglobin. Laboratory abnormalities with occurrence in at least 1 participant are reported for this outcome measure. Baseline was defined as the last pre-dose measurement.
| Participants | PF-06939926: Low Dose, Ambulatory Cohort | PF-06939926: High Dose, Ambulatory Cohort | PF-06939926: High Dose, Non-Ambulatory Cohort |
|---|---|---|---|
| Hemoglobin (g/dL) <0.8x Lower Limit of Normal (LLN) | 0 | 1 | 1 |
| Hematocrit (%)<0.8x LLN | 0 | 2 | 1 |
| Erythrocytes (10^6/mm3)<0.8x LLN | 0 | 1 | 1 |
| Platelets (10^3/mm3)<0.5x LLN | 0 | 5 | 1 |
| Erythrocyte Cell Morphology (No Unit)>0 | 0 | 1 | 1 |
| Leukocytes (10^3/mm3)>1.5x Upper Limit of Normal (ULN) | 0 | 2 | 1 |
| Lymphocytes (10^3/mm3)<0.8x LLN | 1 | 6 | 2 |
| Lymphocytes (10^3/mm3)>1.2x ULN | 0 | 2 | 1 |
| Lymphocytes Atypical (10^3/mm3)>0 | 1 | 9 | 2 |
| Neutrophils (10^3/mm3)<0.8x LLN | 0 | 2 | 0 |
| Neutrophils (10^3/mm3)>1.2x ULN | 1 | 7 | 2 |
| Neutrophils Band Form (10^3/mm3)>0.27 | — | 0 | 1 |
| Basophils (10^3/mm3)>1.2x ULN | 0 | 1 | 0 |
| Eosinophils (10^3/mm3)>1.2x ULN | 1 | 2 | 0 |
| Monocytes (10^3/mm3)>1.2x ULN | 0 | 12 | 3 |
| Activated Partial Thromboplastin Time (sec)>1.1x ULN | 1 | 1 | 0 |
| Prothrombin Time (sec)>1.1x ULN | 1 | 7 | 2 |
| Neutrophils -TOTAL COUNT (10^3/mm3)<1.35 | 0 | 2 | 0 |
| Neutrophils -TOTAL COUNT (10^3/mm3)>8.15 | 2 | 14 | 2 |
| Myelocytes (10^3/mm3)>0 | — | 1 | — |
| Haptoglobin (mg/dL)<30 | — | 3 | 1 |
| Haptoglobin (mg/dL)>200 | 0 | 10 | 3 |
Following parameters for clinical chemistry were analyzed for laboratory examination: blood urea nitrogen (BUN) and creatinine, glucose, calcium, sodium, potassium, chloride, total CO2 (bicarbonate), aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin (direct and indirect bilirubin), alkaline phosphatase, uric acid, albumin, total protein, serum phosphorus, cystatin C, creatine kinase, creatine kinase myocardial b fraction (CK-MB), amylase, lipase, gamma-glutamyl transferase (GGT), C-reactive protein (CRP), and cardiac troponin I. Laboratory abnormalities with occurrence in at least 1 participant are reported for this outcome measure. Baseline was defined as the last pre-dose measurement.
| Participants | PF-06939926: Low Dose, Ambulatory Cohort | PF-06939926: High Dose, Ambulatory Cohort | PF-06939926: High Dose, Non-Ambulatory Cohort |
|---|---|---|---|
| Bilirubin (mg/dL)>1.5x ULN | 0 | 0 | 1 |
| Direct Bilirubin (mg/dL)>1.5x ULN | 0 | 0 | 1 |
| Aspartate Aminotransferase (U/L)>3.0x ULN | 3 | 16 | 3 |
| Alanine Aminotransferase (U/L)>3.0x ULN | 3 | 16 | 3 |
| Gamma Glutamyl Transferase (U/L)>3.0x ULN | 0 | 1 | 1 |
| Protein (g/dL)<0.8x LLN | 0 | 2 | 0 |
| Albumin (g/dL)<0.8x LLN | 0 | 0 | 1 |
| Urea Nitrogen (mg/dL)>1.3x ULN | 0 | 1 | 1 |
| Creatinine (mg/dL)>1.3x ULN | 0 | 1 | 1 |
| Urate (mg/dL)>1.2x ULN | 0 | 6 | 0 |
| Sodium (mEq/L)<0.95x LLN | 0 | 1 | 2 |
| Potassium (mEq/L)<0.9x LLN | 0 | 1 | 1 |
| Calcium (mg/dL)<0.9x LLN | 0 | 0 | 1 |
| Phosphate (mg/dL)<0.8x LLN | 0 | 2 | 1 |
| Bicarbonate (mEq/L)<0.9x LLN | 0 | 2 | 2 |
| Bicarbonate (mEq/L)>1.1x ULN | 0 | 1 | 0 |
| Glucose (mg/dL)>1.5x ULN | 0 | 4 | 2 |
| Creatine Kinase (U/L)>2.0x ULN | 3 | 16 | 3 |
| Triacylglycerol Lipase (U/L)>1.5x ULN | 0 | 0 | 1 |
| C-Reactive Protein High Sens (mg/dL)>1.1x ULN | 0 | 3 | 2 |
| Cystatin C (mg/L)>1.2x ULN | 0 | 3 | 1 |
| Creatine Kinase MB (ug/L)>2.0x ULN | 3 | 16 | 2 |
| Glutamate Dehydrogenase (U/L)>1.0x ULN | 2 | 10 | 3 |
| Glutamate Dehydrogenase (U/L)>2.0x ULN | 0 | 5 | 2 |
| Glutamate Dehydrogenase (U/L)>3.0x ULN | 0 | 3 | 2 |
| Ferritin (ng/mL)<23.9 | 0 | 8 | 0 |
| Ferritin (ng/mL)>336.2 | 0 | 11 | 3 |
Following parameters for urinalysis were analyzed for laboratory examination: pH, glucose, protein, blood, ketones, nitrites, leukocyte esterase, and microscopy. Laboratory abnormalities with occurrence in at least 1 participant are reported for this outcome measure. Baseline was defined as the last pre-dose measurement.
| Participants | PF-06939926: Low Dose, Ambulatory Cohort | PF-06939926: High Dose, Ambulatory Cohort | PF-06939926: High Dose, Non-Ambulatory Cohort |
|---|---|---|---|
| URINE Ketones (No Unit)>=1 | 0 | 7 | 3 |
| URINE Protein (Scalar)>=1 | 0 | 2 | 1 |
| URINE Hemoglobin (No Unit)>=1 | 0 | 4 | 1 |
| URINE Nitrite (No Unit)>=1 | 0 | 1 | 0 |
| URINE Erythrocytes (/high-powered field [HPF])>=20 | 0 | 1 | 0 |
| URINE Leukocytes (/HPF)>=20 | — | 1 | 0 |
| Granular Casts (/low-power field [LPF])>1 | — | 1 | — |
| Hyaline Casts (/LPF)>1 | — | 1 | — |
| Uric Acid Crystals (/LPF)>=0.5 | — | 2 | — |
| Calcium Oxalate Crystals (/LPF)>=0.5 | 2 | 2 | 1 |
| Amorphous Crystals (/LPF)>=0.5 | 0 | 7 | 1 |
| Urine Microscopic Exam (Scalar)>=1 | 2 | 14 | 3 |
Cardiac MRI was performed after thigh and upper limb MRI or on separate days within the required visit window. Change in LVEF is presented as percentages, and was calculated as \[(stroke volume) / (end-diastolic volume)\]\*100%. Baseline is defined as the last pre-dose measurement. Change from baseline on Day 360 (ie, 1 year post dose) was reported for this outcome measure.
| Percentage | PF-06939926: Low Dose, Ambulatory Cohort | PF-06939926: High Dose, Ambulatory Cohort | PF-06939926: High Dose, Non-Ambulatory Cohort |
|---|---|---|---|
| Change From Baseline on Left Ventricular Ejection Fraction as Measured by Cardiac Magnetic Resonance Imaging (MRI) for 1-Year Follow-Up | -0.7 ± 3.2 | -1.0 ± 4.3 | -3.1 ± 1.8 |
Triplicate ECG was performed after the participant had rested quietly for at least 10 minutes in a supine position. The pre-defined categorical criteria include PR interval aggregate (msec): value\>=300, baseline\>200 and percent change\>=25%, baseline\<=200 and percent change\>=50%; QRS duration aggregate (msec): value\>=140, percent change\>=50%; QTcF interval aggregate (msec): 450\<=value\<480, 480\<=value\<500, value\>=500, 30\<=change\<60, change\>=60. Only the category(ies) with at least 1 participant meeting the pre-defined criterion is/are reported for this outcome measure. Baseline for ECG was defined as the measurement before the Day 1 study drug administration.
| Participants | PF-06939926: Low Dose, Ambulatory Cohort | PF-06939926: High Dose, Ambulatory Cohort | PF-06939926: High Dose, Non-Ambulatory Cohort |
|---|---|---|---|
| Number of Participants With Electrocardiograms (ECGs) Meeting the Pre-Defined Categorical Criteria for 1-Year Follow-Up | 1 | 2 | 0 |
C-SSRS is a participant rated questionnaire to assess whether participant experienced the following: completed suicide(1), suicide attempt(2)("Yes" on "actual attempt"), preparatory acts toward imminent suicidal behavior(3)("Yes" on "preparatory acts or behavior"), suicidal ideation(4)("Yes" on "wish to be dead","non-specific active suicidal thoughts","active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent), any suicidal behavior or ideation, self-injurious behavior(7)("Yes" on "Has subject engaged in non-suicidal self-injurious behavior"). Yes/No responses are mapped to C-CASA categories. C-SSRS was conducted with the participant's care giver/legal guardian on the participant's behalf throughout the study for participants\<=12 years of age at screening. Baseline is defined as the last predose measurement. Number of participants with responses of "Yes" is reported for this outcome measure.
| Participants | PF-06939926: Low Dose, Ambulatory Cohort | PF-06939926: High Dose, Ambulatory Cohort | PF-06939926: High Dose, Non-Ambulatory Cohort |
|---|---|---|---|
| Baseline: Lifetime <1> Completed Suicide | 0 | 0 | 0 |
| Baseline: Lifetime <2> Suicide Attempt | 0 | 0 | 0 |
| Baseline: Lifetime <3> Preparatory Acts towards Imminent Suicidal Behavior | 0 | 0 | 0 |
| Baseline: Lifetime <4> Suicidal Ideation | 0 | 1 | 0 |
| Baseline: Lifetime <7> Self-injurious behavior, no suicidal intent | 0 | 0 | 0 |
| Baseline: Since Last Visit <1> Completed Suicide | 0 | 0 | 0 |
| Baseline: Since Last Visit <2> Suicide Attempt | 0 | 0 | 0 |
| Baseline: Since Last Visit <3> Preparatory Acts towards Imminent Suicidal Behavior | 0 | 0 | 0 |
| Baseline: Since Last Visit <4> Suicidal Ideation | 0 | 0 | 0 |
| Baseline: Since Last Visit <7> Self-injurious behavior, no suicidal intent | 0 | 0 | 0 |
| Day 7: Since Last Visit <1> Completed Suicide | 0 | 0 | 0 |
| Day 7: Since Last Visit <2> Suicide Attempt | 0 | 0 | 0 |
| Day 7: Since Last Visit <3> Preparatory Acts towards Imminent Suicidal Behavior | 0 | 0 | 0 |
| Day 7: Since Last Visit <4> Suicidal Ideation | 0 | 0 | 0 |
| Day 7: Since Last Visit <7> Self-injurious behavior, no suicidal intent | 0 | 0 | 0 |
| Day 14: Since Last Visit <1> Completed Suicide | 0 | 0 | 0 |
| Day 14: Since Last Visit <2> Suicide Attempt | 0 | 0 | 0 |
| Day 14: Since Last Visit <3> Preparatory Acts towards Imminent Suicidal Behavior | 0 | 0 | 0 |
| Day 14: Since Last Visit <4> Suicidal Ideation | 0 | 0 | 0 |
| Day 14: Since Last Visit <7> Self-injurious behavior, no suicidal intent | 0 | 0 | 0 |
| Day 180: Since Last Visit <1> Completed Suicide | 0 | 0 | 0 |
| Day 180: Since Last Visit <2> Suicide Attempt | 0 | 0 | 0 |
| Day 180: Since Last Visit <3> Preparatory Acts towards Imminent Suicidal Behavior | 0 | 0 | 0 |
| Day 180: Since Last Visit <4> Suicidal Ideation | 0 | 0 | 1 |
| Day 180: Since Last Visit <7> Self-injurious behavior, no suicidal intent | 0 | 0 | 0 |
| Day 360: Since Last Visit <1> Completed Suicide | 0 | 0 | 0 |
| Day 360: Since Last Visit <2> Suicide Attempt | 0 | 0 | 0 |
| Day 360: Since Last Visit <3> Preparatory Acts towards Imminent Suicidal Behavior | 0 | 0 | 0 |
| Day 360: Since Last Visit <4> Suicidal Ideation | 0 | 0 | 0 |
| Day 360: Since Last Visit <7> Self-injurious behavior, no suicidal intent | 0 | 0 | 0 |
Vital signs consisted of blood pressure, respiratory rate, and heart rate, was obtained with these measurements at the following timepoints: within 30 minutes before and approximately 30 minutes, 1, 2, 4, 8, and 24 hours after the start of the infusion, and on Days 4, 7, 10, 14, 30, 90, 180, and 360. Baseline was defined as the last pre-dose recording. Number of participants who had at least 1 vital sign measurement at the specified timepoints meeting the pre-defined criteria from baseline up to the end of 1-year follow-up is reported for this outcome measure.
| Participants | PF-06939926: Low Dose, Ambulatory Cohort | PF-06939926: High Dose, Ambulatory Cohort | PF-06939926: High Dose, Non-Ambulatory Cohort |
|---|---|---|---|
| Respiratory Rate: value<14 breaths/min for aged 6-12 years | 0 | 0 | — |
| Respiratory Rate: value>22 breaths/min for aged 6-12 years | 3 | 16 | — |
| Respiratory Rate: value<12 breaths/min for aged 13-18 years | — | — | 0 |
| Respiratory Rate: value>20 breaths/min for aged 13-18 years | — | — | 3 |
| Supine Diastolic Blood Pressure: value<50 mmHg | 1 | 5 | 0 |
| Supine Diastolic Blood Pressure: increase>=20 mmHg | 0 | 2 | 0 |
| Supine Diastolic Blood Pressure: decrease>=20 mmHg | 1 | 2 | 1 |
| Supine Heart Rate: value<40 beats per minute (bpm) | 0 | 0 | 0 |
| Supine Heart Rate: value>120 bpm | 0 | 1 | 1 |
| Supine Systolic Blood Pressure: value<70 mmHg + 2*age for aged 2-10 years | 0 | 0 | — |
| Supine Systolic Blood Pressure: value<90 mmHg for aged 11 years and older | — | 1 | 0 |
| Supine Systolic Blood Pressure: increase from baseline>=30 mmHg | 0 | 5 | 0 |
| Supine Systolic Blood Pressure: decrease from baseline>=30 mmHg | 1 | 0 | 0 |
Collected over Baseline up to the end of 1-year follow-up (approximately 360 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PF-06939926: Low Dose, Ambulatory Cohort | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| PF-06939926: High Dose, Ambulatory Cohort | 0/16 (0%) | 3/16 (18.8%) | 16/16 (100%) |
| PF-06939926: High Dose, Non-Ambulatory Cohort | 1/3 (33.3%) | 2/3 (66.7%) | 3/3 (100%) |
| Event | PF-06939926: Low Dose, Ambulatory Cohort | PF-06939926: High Dose, Ambulatory Cohort | PF-06939926: High Dose, Non-Ambulatory Cohort |
|---|---|---|---|
| Haemolytic uraemic syndromeBlood and lymphatic system disorders | 0/3 | 0/16 | 1/3 |
| Cardiogenic shockCardiac disorders | 0/3 | 0/16 | 1/3 |
| Urinary tract infectionInfections and infestations | 0/3 | 0/16 | 1/3 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/3 | 1/16 | 0/3 |
| DehydrationMetabolism and nutrition disorders | 0/3 | 1/16 | 0/3 |
| Acute kidney injuryRenal and urinary disorders | 0/3 | 1/16 | 0/3 |
| Event | PF-06939926: Low Dose, Ambulatory Cohort | PF-06939926: High Dose, Ambulatory Cohort | PF-06939926: High Dose, Non-Ambulatory Cohort |
|---|---|---|---|
| NauseaGastrointestinal disorders | 2/3 | 8/16 | 3/3 |
| VomitingGastrointestinal disorders | 2/3 | 13/16 | 3/3 |
| HeadacheNervous system disorders | 0/3 | 7/16 | 3/3 |
| Abdominal pain upperGastrointestinal disorders | 0/3 | 3/16 | 2/3 |
| Decreased appetiteMetabolism and nutrition disorders | 2/3 | 6/16 | 0/3 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/3 | 0/16 | 2/3 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/3 | 8/16 | 0/3 |
| PyrexiaGeneral disorders | 1/3 | 8/16 | 0/3 |
| FatigueGeneral disorders | 1/3 | 6/16 | 0/3 |
| LeukocytosisBlood and lymphatic system disorders | 1/3 | 0/16 | 0/3 |
Includes all enrolled participants who received PF-06939926 as of the PCD data cutoff (30 Sep 2022). Participants were analyzed according to the intervention they actually received.
| Age, Customized(Participants) | PF-06939926: Low Dose, Ambulatory Cohort | PF-06939926: High Dose, Ambulatory Cohort | PF-06939926: High Dose, Non-Ambulatory Cohort | Total |
|---|---|---|---|---|
| 6-<7 years | 0 | 2 | 0 | 2 |
| 7-<8 years | 1 | 4 | 0 | 5 |
| 8-<9 years | 1 | 4 | 0 | 5 |
| 9-<10 years | 1 | 4 | 0 | 5 |
| 10-<11 years | 0 | 1 | 0 | 1 |
| 11-<12 years | 0 | 0 | 0 | 0 |
| >=12 years | 0 | 1 | 3 | 4 |
| Age, Customized(Years) | PF-06939926: Low Dose, Ambulatory Cohort | PF-06939926: High Dose, Ambulatory Cohort | PF-06939926: High Dose, Non-Ambulatory Cohort | Total |
|---|---|---|---|---|
| Median | 8 (7 to 9) | 8 (6 to 12) | 14 (13 to 16) | 8 (6 to 16) |
| Sex: Female, Male(Participants) | PF-06939926: Low Dose, Ambulatory Cohort | PF-06939926: High Dose, Ambulatory Cohort | PF-06939926: High Dose, Non-Ambulatory Cohort | Total |
|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 |
| Male | 3 | 16 | 3 | 22 |
| Race/Ethnicity, Customized(Participants) | PF-06939926: Low Dose, Ambulatory Cohort | PF-06939926: High Dose, Ambulatory Cohort | PF-06939926: High Dose, Non-Ambulatory Cohort | Total |
|---|---|---|---|---|
| White | 3 | 13 | 1 | 17 |
| Black or African American | 0 | 1 | 1 | 2 |
| Asian | 0 | 2 | 0 | 2 |
| Not Reported | 0 | 0 | 1 | 1 |
| Mutation Type(Participants) | PF-06939926: Low Dose, Ambulatory Cohort | PF-06939926: High Dose, Ambulatory Cohort | PF-06939926: High Dose, Non-Ambulatory Cohort | Total |
|---|---|---|---|---|
| Deletion | 1 | 0 | 0 | 1 |
| Exon Deletion | 1 | 7 | 2 | 10 |
| Exon Duplication | 0 | 3 | 0 | 3 |
| Insertion | 0 | 1 | 0 | 1 |
| Point Mutation | 1 | 4 | 1 | 6 |
| Cryptic Splice Donor Site | 0 | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Ran from Jan 2018 to primary completion in Mar 2022, 50 months.
Results were first posted in Sep 2024, 2 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Muscular Dystrophy, Duchenne →